Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma

* Patient has confirmed clinical diagnosis of SMM according to a definition derived from the International Myeloma Working Group (IMWG) definition: serum M-protein ≥3 g/dL or bone marrow clonal plasma cells (BMPC) greater than or equal to 10%, or both, along with normal organ and marrow function (CRAB) within 4 weeks before baseline. * C: Absence of hypercalcemia, evidenced by a calcium \<10.5 mg/dL. * R: Absence of renal failure, evidenced by a creatinine \<2.0 mg/dL or calculated creatinine clearance (using the Modification of Diet in Renal Disease \[MDRD\] formula) \>50 mL/min. * A: Absence of anemia, evidenced by a hemoglobin \>10 g/dL. * B: Absence of lytic bone lesions on standard skeletal survey. * Patient is at higher than average risk of progression to active MM, defined as having 2 or more of the following features: * Serum monoclonal (M)-protein ≥3 g/dL. * BMPC greater than or equal to 10%. * Abnormal serum free light chain (FLC) ratio (0.26-1.65). * Patient has a life expectancy of greater than 6 months * Patient is human leukocyte antigen (HLA)-A2 positive. * Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Patient has adequate bone marrow function, evidenced by a platelet count ≥75×109/L and an absolute neutrophil count (ANC) ≥1.0×109/L within 2 weeks before baseline. * Patient has adequate hepatic function, evidenced by a bilirubin ≤2.0 mg/dL and an alanine transaminase (ALT), and aspartate transaminase (AST) ≤2.5× the upper limit of normal (ULN) within 2 weeks before baseline. * If of child-bearing potential, patient agrees to use adequate birth control measures during study participation. * If a female of child-bearing potential, patient has negative urine pregnancy test results within 2 weeks before baseline and is not lactating. * Patient (or his or her legally accepted representative) has provided written informed consent to participate in the study. Exclusion Criteria: * Patient has symptomatic multiple myeloma, as defined by any of the following: * Lytic lesions or pathologic fractures. * Anemia (hemoglobin \<10 g/dL). * Hypercalcemia (corrected serum calcium \>11.5 mg/dL). * Renal insufficiency (creatinine \>2 mg/dL). * Other: symptomatic hyperviscosity, amyloidosis. * Patient has abnormal cardiac status, evidenced by any of the following: * New York Heart Association (NYHA) stage III or IV congestive heart failure (CHF). * Myocardial infarction within the previous 6 months. * Symptomatic cardiac arrhythmia requiring treatment or persisting despite treatment. * Patient is receiving any other investigational agent. * Patient has a current active infectious disease or positive serology for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV). * Patient has a history of or current auto-immune disease. * Patient has been vaccinated with live attenuated vaccines within 4 weeks before study vaccination.